Increase in Low-Density Lipoprotein Cholesterol In the pool of 13 placebo-controlled trials of glycemic control, changes from baseline in mean lipid values were reported in dapagliflozin-treated adult patients compared to placebo-treated patients
Second-generation GLP-1 drugs contain an added hormone, gastrointestinal inhibitory peptide (GIP), which further enhances the bodys ability to manage blood sugar and shed weight
While they target a similar consumer, though, they're very different products
This double action gives it potentially more powerful effects on both weight loss and blood sugar control
In general, essential fatty acid deficiency (i.e., deficiency of both ALA and LA) has been observed only in patients with chronic fat malabsorption, cystic fibrosis, or those on parenteral nutrition without PUFA (86, 95) (see the article on Essential Fatty Acids)